Cost-effectiveness analysis of donafenib and sorafenib as a first-line treatment for unresectable or metastatic hepatocellular carcinoma

JU Wenxiang, ZHANG Xiaohan, ZHAO Yingying, LU Luolan, SHEN Aizong

Chinese Journal of Hospital Pharmacy ›› 2024, Vol. 44 ›› Issue (8) : 946-950.

PDF(780 KB)
PDF(780 KB)
Chinese Journal of Hospital Pharmacy ›› 2024, Vol. 44 ›› Issue (8) : 946-950. DOI: 10.13286/j.1001-5213.2024.08.14
Drug and Clinical

Cost-effectiveness analysis of donafenib and sorafenib as a first-line treatment for unresectable or metastatic hepatocellular carcinoma

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2024, 44(8): 946-950 https://doi.org/10.13286/j.1001-5213.2024.08.14

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(780 KB)

Accesses

Citation

Detail
Sections
Recommended
Information
Governed by: China Association for Science and Technology
Sponsored by: Chinese Pharmaceutical Association
Published by: Editorial Office of Chinese Journal of Hospital Pharmacy
ISSN 1001-5213
CN 42-1204/R
Contact
Website Copyright © Chinese Journal of Hospital Pharmacy, All Rights Reserved.
Tel: 027-82836596
E-mail：pharmacy@vip.163.com
Wechat

/

〈 〉